Cargando…
Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literature
SARS‐CoV‐2 infection can cause severe pneumonia (COVID‐19). There is evidence that patients with comorbidities are at higher risk of a severe disease course. The role of immunosuppression in the disease course is not clear. In the present report, we first describe two cases of persisting SARS‐CoV‐2...
Autores principales: | Tepasse, Phil‐Robin, Hafezi, Wali, Lutz, Mathias, Kühn, Joachim, Wilms, Christian, Wiewrodt, Rainer, Sackarnd, Jan, Keller, Martin, Schmidt, Hartmut H., Vollenberg, Richard |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7300950/ https://www.ncbi.nlm.nih.gov/pubmed/32557623 http://dx.doi.org/10.1111/bjh.16896 |
Ejemplares similares
-
Reduced Vitamin A RBP Levels in Hospitalized COVID-19 Patients
por: Tepasse, Phil-Robin, et al.
Publicado: (2022) -
Discrimination of COVID‐19 From Inflammation‐Induced Cytokine Storm Syndromes Using Disease‐Related Blood Biomarkers
por: Kessel, Christoph, et al.
Publicado: (2021) -
Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID‐19 vaccination
por: Riise, Jon, et al.
Publicado: (2022) -
B Cell Numbers Predict Humoral and Cellular Response Upon SARS–CoV‐2 Vaccination Among Patients Treated With Rituximab
por: Stefanski, Ana‐Luisa, et al.
Publicado: (2022) -
First back-calculation and infection fatality multiplier estimate of the hidden prevalence of COVID-19 in Ireland
por: Comiskey, Catherine M, et al.
Publicado: (2021)